MEMatthias P. A. Ebert

Matthias P. A. Ebert

*This is an algorithmically generated author record based on publicly available information.

Matthias P. A. Ebert has a total of 74 co-authors. Here are the top co-authors by number of shared publications:

  • Peter Malfertheiner

    Department of Gastroenterology, Hepatology and Infectious Diseases; Institutes of

    13 shared publications
  • Christoph Röcken

    Department of Pathology, University Hospital Schleswig-Holstein, Kiel, Germany

    10 shared publications
  • Jie Chen

    Department of Gastroenterology, Hepatology, and Infectious Diseases, Otto-von-Guericke University, Leipzigerstr. 44, D-39120 Magdeburg, Germany

    5 shared publications
  • Jun Yu

    Institute of Digestive Disease, Department of Medicine and Therapeutics, State Key Laboratory of Digestive Disease, Li Ka Shing Institute of Health Sciences, CUHK Shenzhen Research Institute, The Chinese University of Hong Kong, Hong Kong SAR, China

    4 shared publications
  • P Malfertheiner

    Department of Gastroenterology, Hepatology, and Infectious Diseases, Otto-von-Guericke University, Magdeburg, Germany

    4 shared publications
  • Alba Rocco

    Department of Clinical Medicine and Surgery, Gastroenterology Unit, University Federico II, Naples, Italy

    3 shared publications

Latest Publications

  • Neue Wege zur Früherkennung, Prognoseabschätzung und Therapie maligner Tumoren des Gastrointestinaltraktes

    by C Röcken, U Neumann, M Ebert

    Gastrointestinale Tumoren sind mit einer weltweiten Zahl von ca. 2 Millionen Neuerkrankungen und 1,2 Millionen Sterbefällen pro Jahr die häufigsten malignen Tumoren des Menschen. Sie sind meistens Erkrankungen des Seniums. Bei kontinuierlich steigender Lebenserwartung in den westlichen Industrienationen nimmt ihre relative und absolute Häufigkeit kontinuierlich zu. Nur so ist zu erklären, warum das distale Magenkarzinom bei abnehmender Inzidenz eine steigende Prävalenz aufweist. Gastrointestinale Tumoren werden auch zukünftig ein immanentes klinisches und gesundheitsökonomisches Problem darstellen. Ihre Prognose ist oft schlecht, da sie meistens zu spät diagnostiziert werden und die therapeutischen Optionen dann nur noch eingeschränkt sind. Um diesen Problemen zu begegnen, müssen Strategien entwickelt werden, die eine Identifikation von Risikopatienten und Tumoren im Frühstadium erlauben und auf eine breitere Akzeptanz in der Bevölkerung stoßen. Es sollten prognostische und prädiktive Biomarker entwickelt und in der Klinik eingesetzt werden, die auch im Stande sind, eine Therapie in den verschiedenen Stadien einer Tumorerkrankung zu lenken. Tumours of the gastrointestinal tract are the single largest group of malignant tumours of humans accounting for approximately 2 million new cases and over 1.2 million deaths annually. They are most commonly a disease of the elderly, and their relative and absolute frequency will rise continuously due to an ageing population. This explains why the prevalence of gastric cancer increases in spite of a decreasing incidence. Gastrointestinal tumours will remain a major clinical and health economical challenge. The prognosis is often dismal. Most of these cancers are diagnosed in an advanced stage, which prohibits curative treatment and limits treatment options. In order to circumvent these problems, we need to develop strategies that allow identification of at-risk patients and tumours at an early stage, and raise the compliance in the general population for screening programmes. There is a great need in clinics for prognostic and predictive biomarkers that are able to tailor patient treatment at different stages of the disease.


  • Open Access

    The Angiotensin I–Converting Enzyme Gene Insertion/Deletion Polymorphism Is Linked to Early Gastric Cancer

    by Matthias P.A. Ebert, Uwe Lendeckel, Sabine Westphal, Jutta Dierkes, JürGen Glas, Christian Folwaczny, Albert Roessner, Manfred Stolte, Peter Malfertheiner, Christoph RöcKen

    The insertion/deletion polymorphism of the angiotensin I–converting enzyme (ACE) gene has recently been linked to the pathogenesis and progression of human cancers. Using genomic DNA from 88 patients with early gastric cancer confined either to mucosa (pT1a) or submucosa (pT1b), we assessed the insertion (I) and deletion (D) polymorphism by PCR analysis and compared it with a large noncancer control population (n = 145). In the noncancer control group, the II genotype was observed in 33 (23%) individuals, whereas the ID and DD genotypes were found in 72 (50%) and 40 (27%) individuals, respectively. Interestingly, in the cancer group, we found the II genotype in six (7%) patients and the ID genotype in 46 (52%) individuals, whereas the DD genotype was observed in 36 (41%) individuals (P = 0.0034). Accordingly, the odds ratio for the II genotype was 0.20 [95% confidence interval (95% CI), 0.08-0.54; P = 0.009] and 0.55 for the ID/II genotype (95% CI, 0.31-0.96; P = 0.044) using the high-activity genotype DD as the reference category. No correlation was found among tumor type, tumor stage, the presence of Helicobacter pylori, and the ACE genotype. Our study provides further evidence that the ACE insertion/deletion gene polymorphism may be linked to the development of early gastric cancer. (Cancer Epidemiol Biomarkers Prev 2005;14(12):2987–9)


  • Open Access

    Hypermethylation of the TPEF/HPP1 Gene in Primary, Metastatic Colorectal Cancers

    by Matthias P.A. Ebert, Suzanne H. Mooney, Lori Tonnes-Priddy, Joe Lograsso, Juliane Hoffmann, Jie Chent, Christoph Rocken, Hans-Ulrich Schulz, Peter Malfertheiner, Catherine Lofton-Day


  • Open Access

    Expression of carbonic anhydrase 9 at the invasion front of gastric cancers

    by J Chen, C Röcken, J Hoffmann, S Krüger, U Lendeckel, A Rocco, S Pastorekova, P Malfertheiner, M P A Ebert

    Background: Carbonic anhydrase IX (MN/Ca9) catalyses the reversible metabolism of carbon dioxide to carbonic acid and has also been linked to malignant transformation and hypoxia in various cancers. Aims: To assess the expression and biological role of Ca9 in gastric cancer. Methods: Using gastric cancer cell lines and tissues, we studied expression of Ca9 by western blot analysis, immunohistochemistry, and polymerase chain reaction. Biological changes after Ca9 transfection and after treatment with 5′-azadeoxycytidine were also analysed in cancer cell lines. Results: Non-cancerous tissues strongly expressed Ca9 with membranous localisation. In contrast, Ca9 expression was frequently lost in gastric cancers (pConclusions: A subgroup of gastric cancers retain Ca9 expression in cancer cells at the invasion front. While loss of Ca9 expression is regulated in part by methylation, re-expression of Ca9 is associated with increased invasion, supporting the hypothesis that increased Ca9 expression may contribute to invasion and thus advanced disease and tumour progression in a subset of gastric cancers.


  • The tyrosine kinase inhibitor imatinib fails to inhibit pancreatic cancer progression

    by Jie Chen, Christoph Röcken, Barbara Nitsche, Christian Hosius, Harald Gschaidmeier, Stefan Kahl, Peter Malfertheiner, Matthias P.A. Ebert


  • Identification of the Thrombin Light Chain A as the Single Best Mass for Differentiation of Gastric Cancer Patients from Individuals with Dyspepsia by Proteome Analysis

    by Matthias P. A. Ebert, Stephanie Lamer, Jörn Meuer, Peter Malfertheiner, Marc Reymond, Thomas Buschmann, Christoph Röcken, Volker Seibert

    Gastric cancer mortality is second only to lung cancer, and its prognosis is dismal. Using surface-enhanced laser desorption/ionization-time-of-flight mass spectrometry, we previously identified a single best mass, which could separate gastric cancer from patients without cancer, with a sensitivity of 89.9% and a specificity of 90%. Using protein liquid chromatography systems with various chromatography media and MS/MS analysis, we were able to identify thrombin light chain A, a proteolytic fragment of prothrombin, as the single best mass for early detection of gastric cancer patients. These findings indicate that disturbances in the coagulation-system are early events in gastric cancer biology and that a decrease or loss of thrombin light chain A, which we termed negative serum protein profiling, may contribute to the diagnosis of cancer patients. Keywords: gastric • carcinoma • stomach • SELDI • biomarker • thrombin • thrombosis • diagnosis


  • Open Access

    Molecular analysis of APC promoter methylation and protein expression in colorectal cancer metastasis

    by Jie Chen, Christoph Röcken, Cathy Lofton-Day, Hans-Ulrich Schulz, Oliver Müller, Nadine Kutzner, Peter Malfertheiner, Matthias P.A. Ebert

    APC (adenomatous polyposis coli) promoter methylation has been linked to the early development of colorectal cancers. However, the role of APC methylation and its effect on protein expression in colon cancer metastasis is largely unknown. In this study, we investigated APC promoter methylation by Methylight analysis and analysed the APC protein levels by immunohistochemistry and western blot analysis in 24 liver metastasis and 39 primary colorectal cancers. Promoter methylation of the APC gene was found to be a frequent event in liver metastasis (10/24) and significantly more frequent compared with primary colorectal cancer (7/39, P = 0.047). APC methylation was not found in 14 matched normal colon tissues. APC protein was detected in the cytoplasm of primary and metastatic cancer cells and non-tumorous colon epithelium. By western blot analysis, APC protein levels were found to be decreased in primary tumour tissues compared with the normal colon mucosa. In contrast, APC protein levels were not decreased in the cancer cells that had metastasized to the liver. APC protein levels were independent of the presence of APC promoter methylation or gene mutations. In summary, APC promoter methylation is a frequent epigenetic alteration in colorectal cancer metastasis. However, we observed no significant association between APC promoter methylation or gene mutation and APC protein expression in colorectal metastasis. Therefore, metastatic cancer cells seem to harbour a heterogenous genetic and epigenetic background, in which cancer cells may exhibit APC promoter methylation that is independent of APC expression.


  • Microarray analysis of gene expression in metastatic gastric cancer cells after incubation with the methylation inhibitor 5-aza-2′-deoxycytidine

    by Jie Chen, Christoph Röcken, Ludger Klein-Hitpass, Tobias Götze, Andreas Leodolter, Peter Malfertheiner, Matthias P.A. Ebert


  • Identification of Gastric Cancer Patients by Serum Protein Profiling

    by Matthias P. A. Ebert, Jörn Meuer, Jan C. Wiemer, Hans-Ulrich Schulz, Marc A. Reymond, Ulrich Traugott, Peter Malfertheiner, Christoph Röcken

    Using surface-enhanced laser desorption ionization mass spectrometry (SELDI/TOF−MS) and ProteinChip technology, coupled with a pattern-matching algorithm and serum samples, we screened for protein patterns to differentiate gastric cancer patients from noncancer patients. A classifier ensemble, consisting of 50 decision trees, correctly classified all gastric cancers and all controls of a training set (100% sensitivity and 100% specificity). Eight of 9 stage I gastric cancers (88.9% sensitivity for stage I) were correctly classified. In addition, 28 sera from gastric cancer patients taken in different hospitals were correctly classified (100% sensitivity). Furthermore, all 11 control sera obtained from patients without gastric cancer (100% specificity) were classified correctly and 29 of 30 healthy blood-donors were classified as noncancerous. ProteinChip technology in conjunction with bioinformatics allows the highly sensitive and specific recognition of gastric cancer patients. Keywords: Proteomics • diagnosis • stomach • SELDI


  • Expression of caveolin-1 in gastrointestinal and extraintestinal cancers

    by Jie Chen, Zsolt Tulassay, Peter Malfertheiner, Matthias P. A. Ebert, Márk Juhász

    Caveolae are uniform vesicular invaginations of the cell membrane. Caveolin-1 is responsible for the formation of caveolae and plays a key role in membrane traffic and signal transduction. The contribution of caveolin-1 to carcinogenesis has been widely investigated; however, the expression pattern of caveolin-1 is controversial both in gastrointestinal and extraintestinal cancers. Most of the results based on cancer cell line experiments suggest that caveolin-1 might act as a tumor-suppressor gene. On the contrary, several studies on the expression of caveolin-1 in tumor tissues indicate a possible tumor-promoting effect of caveolin-1. In this article we summarize the divergent results of caveolin-1 expression in gastrointestinal and extraintestinal cancer regarding possible future therapeutic implications.